Scarica l'app Stockscreener
118.73
0.64%
0.75
Dopo l'orario di chiusura:
117.40
-1.33
-1.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$117.98
Aprire:
$118.57
Volume 24 ore:
5.39M
Relative Volume:
0.77
Capitalizzazione di mercato:
$147.32B
Reddito:
$28.80B
Utile/perdita netta:
$6.31B
Rapporto P/E:
23.65
EPS:
5.02
Flusso di cassa netto:
$9.37B
1 W Prestazione:
-1.17%
1M Prestazione:
+9.71%
6M Prestazione:
+7.91%
1 anno Prestazione:
+58.84%
Intervallo 1D:
$118.46
$120.89
Intervallo di 1 settimana:
$117.07
$120.89
Portata 52W:
$74.80
$121.83
Gilead Sciences Inc Stock (GILD) Company Profile
Nome
Gilead Sciences Inc
Settore
Industria
Telefono
(650) 574-3000
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Confronta GILD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
118.73 | 146.40B | 28.80B | 6.31B | 9.37B | 5.02 |
|
LLY
Lilly Eli Co
|
705.44 | 625.77B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.84 | 424.47B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
209.15 | 364.92B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
127.25 | 240.07B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.66 | 210.36B | 63.43B | 16.42B | 14.72B | 6.49 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-08 | Aggiornamento | Truist | Hold → Buy |
| 2025-07-25 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Reiterato | Oppenheimer | Outperform |
| 2025-02-18 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Aggiornamento | DZ Bank | Hold → Buy |
| 2025-01-10 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2024-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Reiterato | Maxim Group | Buy |
| 2024-04-24 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Downgrade | Truist | Buy → Hold |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-09-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-09-06 | Iniziato | HSBC Securities | Reduce |
| 2023-07-24 | Reiterato | Barclays | Equal Weight |
| 2023-05-16 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Ripresa | Piper Sandler | Overweight |
| 2023-01-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Ripresa | BofA Securities | Neutral |
| 2022-12-09 | Downgrade | DZ Bank | Buy → Hold |
| 2022-10-31 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Reiterato | BMO Capital Markets | Market Perform |
| 2022-10-28 | Reiterato | Cowen | Outperform |
| 2022-10-28 | Reiterato | JP Morgan | Overweight |
| 2022-10-28 | Reiterato | Jefferies | Buy |
| 2022-10-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-10-28 | Aggiornamento | Truist | Hold → Buy |
| 2022-10-28 | Reiterato | Wells Fargo | Equal Weight |
| 2022-10-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-28 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-02 | Reiterato | BofA Securities | Neutral |
| 2022-02-02 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-02-02 | Reiterato | Truist | Hold |
| 2022-02-02 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Argus | Hold → Buy |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Ripresa | Piper Sandler | Neutral |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-07-30 | Reiterato | BMO Capital Markets | Market Perform |
| 2021-07-30 | Reiterato | RBC Capital Mkts | Outperform |
| 2021-04-01 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-01-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-09-30 | Ripresa | Jefferies | Buy |
| 2020-09-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-31 | Reiterato | Credit Suisse | Neutral |
| 2020-07-31 | Reiterato | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Reiterato | Piper Sandler | Overweight |
| 2020-07-31 | Reiterato | RBC Capital Mkts | Outperform |
| 2020-07-31 | Reiterato | SunTrust | Hold |
| 2020-07-31 | Reiterato | Wells Fargo | Equal Weight |
| 2020-07-20 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Aggiornamento | SunTrust | Sell → Hold |
| 2020-05-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Downgrade | SunTrust | Hold → Sell |
| 2020-04-27 | Downgrade | UBS | Buy → Neutral |
| 2020-04-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Downgrade | CFRA | Hold → Sell |
Mostra tutto
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Exclusive: CVS holds off adding Gilead’s new HIV prevention shot to drug coverage lists - Reuters
Gilead Sciences to Present at Upcoming Investor Conferences - Business Wire
Goldman Sachs Reiterates a Hold Rating on Gilead Sciences (GILD) - MSN
Stock Analysis | Gilead Sciences OutlookTechnical Momentum Gathers, But Earnings May Determine Short-Term Fate - AInvest
Ligand to Participate in September Investor Conferences - GlobeNewswire Inc.
We are positive on Gilead Sciences' base business growth: Meacham - BNN Bloomberg
Gilead attacks remdesivir patent of Chinese research institute at UPC - JUVE Patent
Insider Selling at Gilead Sciences: A Signal of Liquidity or a Cautionary Tale? - AInvest
Mizuho Securities Keeps Buy Rating on Gilead Sciences with $131 Target - AInvest
Exas, Guardant, Gilead among gainers as Supreme Court ensures free preventive care - MSN
Gilead Sciences CCO Mercier sells $3.3m in shares - Investing.com
Gilead Sciences Inc. Stock Recovery Path — Analyst BreakdownJuly 2025 Outlook & Community Verified Swing Trade Signals - beatles.ru
Gilead Sciences CFO sells $296k in shares - Investing.com
GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait? - Nasdaq
Sure, Biogen (BIIB) Has Been on a Hot Streak Recently But My Bet’s on Gilead Sciences (GILD) - Money Morning
Argus Adjusts Price Target on Gilead Sciences to $130 From $120 - MarketScreener
Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use - PMLiVE
Gilead Sciences stock price target raised to $131 from $117 at Mizuho - Investing.com Canada
Mizuho Adjusts Price Target on Gilead Sciences to $131 From $117, Maintains Outperform Rating - MarketScreener
Gilead Sciences' Outperformance Means Overvalued (NASDAQ:GILD) - Seeking Alpha
Short Covering May Lift Gilead Sciences Inc. in Near TermJuly 2025 Patterns & Weekly High Return Forecasts - metal.it
What makes Gilead Sciences Inc. stock attractive todayJuly 2025 Review & Fast Moving Market Watchlists - thegnnews.com
Gilead upgraded to Buy at Needham on new HIV drug - MSN
Gilead Sciences Stock Surges in Trading Volume to 96th Rank Amid 0.55% Drop and Insider Sales - AInvest
Gilead Sciences Appoints New Senior Vice President - The Globe and Mail
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now? - MSN
Gilead Sciences and the Pricing Strategy of Lenacapavir: Balancing Profit and Public Health in the Fight Against HIV - AInvest
Gilead Sciences CEO Says HIV Prevention Drug Offers Clear Value - Bloomberg.com
Gilead Sciences' Triple Negative Breast Cancer Study: A Potential Game-Changer for the Oncology Sector - AInvest
Gilead Sciences Sees Decline in Short Interest, Market Sentiment Remains Unclear - AInvest
Gilead Sciences (GILD) Appoints New Senior Vice President and Pr - GuruFocus
Cantor Fitzgerald Keeps Their Buy Rating on Gilead Sciences (GILD) - The Globe and Mail
Drawing Inspiration from Nature: Olivier Nolan-Stevaux’s Work in Oncology Research - Gilead Sciences
Gilead Sciences' Profit Outlook: Beyond the Numbers - AInvest
We Think Gilead Sciences' (NASDAQ:GILD) Profit Is Only A Baseline For What They Can Achieve - Yahoo Finance
Gilead to buy Nimbus Therapeutics' NASH programme for up to $1.2 billion - FirstWord Pharma
Q2 Rundown: Gilead Sciences (NASDAQ:GILD) Vs Other Therapeutics Stocks - Yahoo Finance
Gilead Sciences’s Q2 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Gilead, J&J Pare Case on Laurus Copy of HIV Drug to Two Patents - Bloomberg Law News
Gilead stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com
Gilead Sciences' Q2 Earnings Call: Growth, Strategic Advances, and Positive Outlook - AInvest
Gilead Sciences' Sacituzumab Govitecan: A Promising New Lung Cancer Treatment - AInvest
Message from the General Manager - Gilead Sciences
Gilead Sciences stock hits 52-week high at 121.67 USD By Investing.com - Investing.com South Africa
Gilead Sciences stock hits 52-week high at 121.67 USD - Investing.com
Gilead Sciences: Strong Q2 Performance and Promising Yeztugo Launch Support Buy Rating - TipRanks
GILD Q2 Deep Dive: HIV Franchise Drives Growth, New Launches and Pipeline in Focus - Yahoo Finance
Gilead Sciences Receives Favorable CHMP Opinion for HIV Prevention Drug Lenacapavir - AInvest
Gilead Sciences’ Earnings Call Highlights Growth and Strategic Advances - TipRanks
Gilead Receives Favorable CHMP Opinion For HIV Prevention With Twice-Yearly Lenacapavir - Insider Monkey
Gilead Sciences Inc (GILD) share price, Expedia Group Inc (EXPE) stocks make record-breaking jump. Details here - MSN
Gilead Sciences Inc Azioni (GILD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Gilead Sciences Inc Azioni (GILD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Commercial Officer |
Aug 15 '25 |
Sale |
118.53 |
28,000 |
3,318,927 |
114,168 |
| Dickinson Andrew D | Chief Financial Officer |
Aug 15 '25 |
Sale |
118.53 |
2,500 |
296,325 |
160,110 |
0.24%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):